Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack (SOCRATES)
Source: View publication →
The SOCRATES trial found that ticagrelor was not statistically superior to aspirin for the prevention of the composite of stroke, myocardial infarction, or death within 90 days in patients with acute ischemic stroke or high-risk transient ischemic attack.
Key Findings
Study Design
Study Limitations
Clinical Significance
Ticagrelor cannot be recommended as a superior alternative to aspirin for the routine secondary prevention of major vascular events in patients with acute, low-acuity ischemic stroke or high-risk TIA. The findings reinforce current guidelines prioritizing aspirin, while identifying potential, yet unproven, utility in specific subsets of patients with established atherosclerotic disease.
Historical Context
The SOCRATES trial was designed to test whether the potent P2Y12 inhibitor ticagrelor, which demonstrated superiority over clopidogrel in the PLATO trial for acute coronary syndromes, would provide similar advantages over aspirin in the acute stroke setting. It represents a key effort in the PARTHENON program to evaluate the efficacy of ticagrelor across various atherothrombotic manifestations.
Guided Discussion
High-yield insights from every perspective
What is the pharmacological mechanism by which ticagrelor inhibits platelet aggregation compared to aspirin, and why would clinicians hypothesize that it might be more effective during the acute phase of a stroke?
Key Response
Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1), preventing the production of thromboxane A2, whereas ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist. Because the P2Y12 pathway is more central to adenosine diphosphate (ADP)-mediated platelet activation, and ticagrelor provides more potent and consistent inhibition than aspirin without requiring metabolic activation (unlike clopidogrel), it was hypothesized to be more effective at preventing early recurrent thrombotic events.
In a patient with a minor ischemic stroke (NIHSS 3) who is not a candidate for thrombolysis, how does the SOCRATES trial influence your decision to use ticagrelor monotherapy versus aspirin, and what safety concerns should you monitor for?
Key Response
The SOCRATES trial showed that ticagrelor was not superior to aspirin for the prevention of the primary composite endpoint (stroke, MI, or death). Therefore, aspirin remains the standard of care for monotherapy. If ticagrelor is used (e.g., in aspirin-allergic patients), residents must monitor for dyspnea and increased rates of minor bleeding, as ticagrelor was associated with significantly higher rates of permanent treatment discontinuation compared to aspirin.
The SOCRATES trial demonstrated a non-significant trend toward benefit for ticagrelor (HR 0.89, p=0.07). However, subgroup analysis suggested a possible benefit in patients with large-artery atherosclerosis (LAA). What is the pathophysiological rationale for why LAA patients might respond better to potent P2Y12 inhibition than those with small-vessel disease?
Key Response
Large-artery atherosclerosis often involves unstable plaques with high shear stress, which triggers significant ADP-mediated platelet activation and recruitment. In contrast, small-vessel disease (lacunar stroke) is often driven by lipohyalinosis or chronic hypertensive changes where acute thrombotic recruitment is less dominant. This suggests that the 'one-size-fits-all' approach to antiplatelets in stroke may be flawed, and etiology-specific therapy might be necessary.
Reflecting on the evolution from SOCRATES to the THALES trial, how should we teach the role of ticagrelor in the context of the 'dual antiplatelet therapy (DAPT) window' for acute minor stroke?
Key Response
SOCRATES taught us that ticagrelor monotherapy is not 'strong enough' to beat aspirin alone in a broad population. However, it paved the way for the THALES trial, which showed that the combination of aspirin and ticagrelor was superior to aspirin alone. This highlights a crucial teaching point: the 'unstable' phase of a stroke requires synergy across different platelet pathways (COX-1 and P2Y12) rather than just a more potent drug in a single pathway.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Critique the use of a 90-day composite endpoint in SOCRATES. How might the inclusion of events occurring between 30 and 90 days have impacted the trial's power to detect a difference in drug efficacy that is arguably most potent in the first 72 hours?
Key Response
The risk of recurrent stroke is front-loaded in the first few days following the index event. By extending the primary endpoint to 90 days, the 'signal' of the drug's immediate effect is diluted by 'noise'—late events that may be less related to the initial thrombotic instability and more related to chronic risk factor management. A more sensitive study design might have utilized a hierarchical endpoint or a primary analysis focused on the first 7-30 days.
As a reviewer, if you noticed that 2.1% of patients in the ticagrelor group discontinued the drug due to dyspnea compared to only 0.1% in the aspirin group, how would you evaluate the threat to the trial's double-blinding and its potential impact on endpoint reporting?
Key Response
Dyspnea is a known, unique side effect of ticagrelor. Because this side effect is so lopsided, it effectively 'unblinds' many investigators and patients to the treatment assignment. This could introduce detection bias for softer endpoints or affect the reporting of secondary adverse events. A rigorous review would require the authors to demonstrate that primary endpoint adjudication remained strictly blinded and independent of local investigator assessments.
The current AHA/ASA guidelines give a Class IIb recommendation for ticagrelor as an alternative to aspirin in patients with contraindications to aspirin. Based on SOCRATES, why was a Class I recommendation not warranted, and how does this compare to the recommendations for Clopidogrel based on the CHANCE trial?
Key Response
A Class I recommendation requires clear evidence of benefit over existing standards. SOCRATES failed to reach its primary endpoint of superiority (p=0.07). In contrast, the CHANCE trial demonstrated clear superiority for DAPT (Aspirin + Clopidogrel) over aspirin alone. Thus, guidelines recommend DAPT as the standard for high-risk TIA/minor stroke. Ticagrelor remains a 'second-line' alternative for monotherapy only when aspirin cannot be used, as it failed to prove it was better than the much cheaper and better-tolerated aspirin.
Clinical Landscape
Noteworthy Related Trials
CHANCE Trial
Tested
Clopidogrel plus aspirin
Population
Patients with high-risk TIA or minor ischemic stroke
Comparator
Aspirin alone
Endpoint
Stroke (ischemic or hemorrhagic) within 90 days
POINT Trial
Tested
Clopidogrel plus aspirin
Population
Patients with minor ischemic stroke or high-risk TIA
Comparator
Aspirin alone
Endpoint
Composite of ischemic stroke, MI, or death from vascular cause at 90 days
THALES Trial
Tested
Ticagrelor plus aspirin
Population
Patients with mild-to-moderate acute non-cardioembolic ischemic stroke or TIA
Comparator
Aspirin alone
Endpoint
Composite of stroke or death within 30 days
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis